PNC Financial Services Group
IKT icon

PNC Financial Services Group’s Inhibikase Therapeutics IKT Stock Holding History

PNC Financial Services Group’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164 Hold
81
– – ﹤0.01% 5115
2026
Q1 		$136 Sell
81
-20
-20% -$36 ﹤0.01% 5076
2025
Q4 		$207 Buy
101
+11
+12% +$18 ﹤0.01% 4975
2025
Q3 		$146 Buy
+90
New +$156 ﹤0.01% 4967

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group's IKT Position: Q2 2026 in Review

PNC Financial Services Group held its Inhibikase Therapeutics (IKT) position steady in Q2 2026 at 81 shares worth $164. The position accounts for ﹤0.01% of the portfolio, ranked #5115.

PNC Financial Services Group first reported a position in IKT in Q3 2025 and has held it in 4 quarters since. The position peaked at $207 in Q4 2025. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • PNC Financial Services Group held 81 shares of Inhibikase Therapeutics worth $164 as of Q2 2026.
  • PNC Financial Services Group left its Inhibikase Therapeutics share count unchanged in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #5115 holding.
  • PNC Financial Services Group first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • PNC Financial Services Group's Inhibikase Therapeutics position peaked at $207 in Q4 2025.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.